


CLAIMS

1. A sulfonamide compound of general formula (Ia),



(Ia)

5 wherein

R¹ represents a -NR⁸R⁹ radical or a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as a ring member containing cycloaliphatic radical, which may be condensed with a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as a ring member containing mono- or bicyclic cycloaliphatic ring system,

R², R³, R⁴, R⁵ and R⁷, identical or different, each represent hydrogen, halogen, nitro, alkoxy, cyano, a saturated or unsaturated, linear or branched, optionally at least mono-substituted aliphatic radical, or an optionally at least mono-substituted phenyl radical or an optionally at least mono-substituted heteroaryl radical,

R⁶ represents hydrogen or a saturated or unsaturated, linear or branched, optionally at least mono-substituted aliphatic radical,

R⁸ and R⁹, identical or different, each represent hydrogen or a saturated or unsaturated, linear or branched, optionally at least mono-substituted aliphatic radical,

with the proviso that R^8 and R^9 are not hydrogen at the same time, and if one of them, R^8 or R^9 , is a saturated or unsaturated, linear or branched, optionally at least mono-substituted C_1 - C_4 aliphatic radical, the other one is a saturated or unsaturated, linear or branched, optionally at least
5 mono-substituted aliphatic radical with at least five carbon atoms,

or

R^8 and R^9 , together with the bridging nitrogen atom, form a saturated or
10 unsaturated, optionally at least mono-substituted heterocyclic ring, which may contain at least one further heteroatom as a ring member and/or which may be condensed with a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as a ring member containing mono- or bicyclic cycloaliphatic ring system,
15

A represents an optionally at least mono-substituted mono- or polycyclic aromatic ring system, which may be bonded via an optionally at least mono-substituted alkylene, alkenylene or alkynylene group and/or which may contain at least one heteroatom as a ring member in one or more of
20 its rings

and


n is 0, 1, 2, 3 or 4;

25 optionally in form of one of its stereoisomers, preferably enantiomers or diastereomers, a racemate or in form of a mixture of at least two of its stereoisomers, preferably enantiomers and/or diastereomers, in any mixing ratio, or a salt thereof, preferably a corresponding, physiologically
30 acceptable salt thereof, or a corresponding solvate thereof.

2. A compound according to claim 1, characterized in that R^1 represents a -
 NR^8R^9 radical or a saturated or unsaturated, optionally at least mono-
 5 substituted, optionally at least heteroatom as a ring member containing
 5- or 6-membered cycloaliphatic radical, which may be condensed with a
 saturated or unsaturated, optionally at least mono-substituted, optionally
 at least one heteroatom as a ring member containing mono- or bicyclic
 cycloaliphatic ring system, whereby the rings of the ring system are 5- or
 6-membered,

10

preferably R^1 represents an $-NR^8R^9$ radical or a radical chosen from the
 group consisting of



- 15 wherein, if present, the dotted line represents an optional chemical bond,
 and R^{10} represents hydrogen, a linear or branched C_1 - C_6 alkyl radical or
 a benzyl radical, preferably hydrogen or a C_1 - C_2 alkyl radical.

3. A compound according to claim 1 or 2, characterized in that R^2 , R^3 , R^4 ,
 R^5 and R^7 , identical or different, each represent hydrogen, a linear or
 20 branched, optionally at least mono-substituted C_1 - C_6 alkyl radical, a linear
 or branched, optionally at least mono-substituted C_2 - C_6 alkenyl radical, or
 a linear or branched, optionally at least mono-substituted C_2 - C_6 alkynyl
 radical,

preferably R^2 , R^3 , R^4 , R^5 and R^7 , identical or different, each represent hydrogen or a linear or branched, optionally at least mono-substituted C_1 - C_6 alkyl radical,

5

more preferably R^2 , R^3 , R^4 , R^5 and R^7 each represent hydrogen.

4. A compound according to one or more of claims 1 to 3, characterized in that R^6 represents hydrogen, a linear or branched, optionally at least mono-substituted C_1 - C_6 alkyl radical, a linear or branched, optionally at least mono-substituted C_2 - C_6 alkenyl radical, a linear or branched, optionally at least mono-substituted C_2 - C_6 alkynyl radical,

10

preferably R^6 represents hydrogen or a linear or branched, optionally at least mono-substituted C_1 - C_6 alkyl radical,

15

more preferably R^6 represents hydrogen or a C_1 - C_2 alkyl radical.

5. A compound according to one or more of claims 1 to 4, characterized in that R^8 and R^9 , identical or different, each represent hydrogen, a linear or branched, optionally at least mono-substituted C_1 - C_{10} alkyl radical, a linear or branched, optionally at least mono-substituted C_2 - C_{10} alkenyl radical, a linear or branched, optionally at least mono-substituted C_2 - C_{10} alkynyl radical,

20

25

or

R^8 and R^9 , together with the bridging nitrogen form a saturated or unsaturated, optionally at least mono-substituted, optionally at least one further heteroatom as a ring member containing 5- or 6-membered heterocyclic ring, which may be condensed with a saturated or unsaturated, optionally at least mono-substituted, optionally at least one

30


heteroatom as a ring member containing mono- or bicyclic cycloaliphatic ring system, whereby the rings of the ring system are 5- 6- or 7-membered.

- 5 6. A compound according to claim 5, characterized in that R^8 and R^9 , identical or different, each represent hydrogen or a linear or branched C_1 - C_{10} alkyl radical,

or

10

R^8 and R^9 , together with the bridging nitrogen form a radical chosen from the group consisting of




- 15 wherein R^{11} represents hydrogen, a linear or branched C_1 - C_6 alkyl radical or a benzyl radical, preferably hydrogen or a C_1 - C_2 alkyl radical.

7. A compound according to one or more of claims 1 to 6, characterized in that A represents an optionally at least mono-substituted mono- or polycyclic aromatic ring system, wherein the ring(s) is/are 5- or 6-membered, which may be bonded via an optionally at least mono-substituted C_1 - C_6 alkylene group, an optionally at least mono-substituted C_2 - C_6 alkenylene group or an optionally at least mono-substituted C_2 - C_6 alkynylene group and/or wherein the ring(s) may contain at least one heteroatom as a ring member,
- 20

-72-

preferably A represents an optionally at least mono-substituted mono- or polycyclic aromatic ring system, wherein the ring(s) is/are 5- or 6-membered and wherein one or more of the rings contain at least one heteroatom,

or a radical chosen from the group consisting of



wherein X, Y, Z, independently from one another, each represent a radical selected from the group consisting of hydrogen, fluorine, chlorine, bromine, linear or branched C₁-C₆ alkyl, linear or branched C₁-C₆ alkoxy, linear or branched C₁-C₆ alkylthio, a trifluoromethyl radical, a cyano radical and a -NR¹²R¹³ radical,

wherein R¹² and R¹³, identical or different, each represent hydrogen or linear or branched C₁-C₆ alkyl,

-73-

W represents a single chemical bond between the two rings, a CH₂, O, S group or a NR¹⁴ radical,

wherein R¹⁴ is hydrogen or a linear or branched C₁-C₆ alkyl,

5

m is 0, 1, 2, 3 or 4 and

m1 is 1 or 2.

- 10 8. A compound according to one or more of claims 1 to 7, selected from the group consisting of

[9] 5-Chloro-3-methyl-N-[1-[2-(pyrrolidin-1-yl)ethyl]-1H-indol-6-yl]-benzo[b]thiophene-2-sulfonamide,

15

[10] N-(1-[2-(Pyrrolidin-1-yl)ethyl]-1H-indol-6-yl)-naphthalene-2-sulfonamide,

[11] N-[1-[2-Pyrrolidin-1-yl]ethyl]-1H-indol-6-yl]-naphthalene-1-sulfonamide,

20

[12] 6-Chloro-N-[1-[2-(pyrrolidin-1-yl)ethyl]-1H-indol-6-yl]-imidazo[2,1-b]thiazole-5-sulfonamide,

25

[13] 4-Phenyl-N-(1-(2-(pyrrolidin-1-yl)ethyl)-1H-indol-6-yl)-benzenesulfonamide

[14] 2-(Naphthyl-1-yl)-N-(1-(2-(pyrrolidin-1-yl) ethyl)-1H-indol-6-yl)-ethansulfonamide,


30

[15] 4-Phenoxy-N-(1-(2-(pyrrolidin-1-yl)ethyl)-1H-indol-6-yl)-benzenesulfonamide and

[16] 3,5-Dichloro-N-(1-(2-(pyrrolidin-1-yl)-1H-indol-6-yl)-benzenesulfonamide,

5 and their corresponding salts and solvates.

9. A sulfonamide compound of general formula (Ib)



(Ib)

10

wherein

R^1 is a $-NR^8R^9$ radical,

15

R^2 , R^3 , R^4 , R^5 and R^7 , identical or different, each represent hydrogen, halogen, nitro, alkoxy, cyano, a saturated or unsaturated, linear or branched, optionally at least mono-substituted aliphatic radical, or an optionally at least mono-substituted phenyl or optionally at least mono-substituted heteroaryl radical,

20

R^6 represents hydrogen or a saturated or unsaturated, linear or branched, optionally at least mono-substituted aliphatic radical,

25

R^8 and R^9 , identical or different, each represent hydrogen or a saturated or unsaturated, linear or branched, optionally at least mono-substituted C_1 - C_4 aliphatic radical,

A represents an optionally at least mono-substituted mono- or polycyclic aromatic ring system, which may be bonded via an optionally at least mono-substituted alkylene, alkenylene or alkynylene group and/or which may contain at least one heteroatom as a ring member in one or more of its rings and

n is 0, 1, 2, 3 or 4;

optionally in form of one of its stereoisomers, preferably enantiomers or diastereomers, a racemate or in form of a mixture of at least two of its stereoisomers, preferably enantiomers and/or diastereomers, in any mixing ratio, or a salt thereof, preferably a corresponding, physiologically acceptable salt thereof, or a corresponding solvate thereof.

10. A compound according to claim 9, characterized in that R^2 , R^3 , R^4 , R^5 and R^7 , identical or different, each represent hydrogen, a linear or branched, optionally at least mono-substituted C_1 - C_6 alkyl radical, a linear or branched, optionally at least mono-substituted C_2 - C_6 alkenyl radical, or a linear or branched, optionally at least mono-substituted C_2 - C_6 alkynyl radical,

preferably R^2 , R^3 , R^4 , R^5 and R^7 , identical or different, each represent hydrogen or a linear or branched, optionally at least mono-substituted C_1 - C_6 alkyl radical,

more preferably R^2 , R^3 , R^4 , R^5 and R^7 each represent hydrogen.

11. A compound according to claim 9 or 10, characterized in that R^6 represents hydrogen, a linear or branched, optionally at least mono-substituted C_1 - C_6 alkyl radical, a linear or branched, optionally at least mono-substituted C_2 - C_6 alkenyl radical, a linear or branched, optionally at least mono-substituted C_2 - C_6 alkynyl radical,

preferably R^6 represents hydrogen or a linear or branched, optionally at least mono-substituted C_1 - C_6 alkyl radical,

5 more preferably R^6 represents hydrogen or a C_1 - C_2 alkyl radical.

12. A compound according to one or more of claims 9 to 11, characterized in that R^8 and R^9 , identical or different, each represent hydrogen or a linear or branched, optionally at least mono-substituted C_1 - C_4 alkyl radical,

10

preferably R^8 and R^9 , identical or different, each represent hydrogen or a C_1 - C_2 alkyl radical,

with the proviso that R^8 and R^9 are not hydrogen at the same time.

15

13. A compound according to one or more of claims 9 to 12, characterized in that A represents an optionally at least mono-substituted mono- or polycyclic aromatic ring system, wherein the ring(s) is/are 5- or 6-membered, which may be bonded via an optionally at least mono-substituted C_1 - C_6 alkylene group, an optionally at least mono-substituted C_2 - C_6 alkenylene group or an optionally at least mono-substituted C_2 - C_6 alkynylene group and/or wherein the ring(s) may contain at least one heteroatom as a ring member,


20

25 preferably A represents an optionally at least mono-substituted mono- or polycyclic aromatic ring system, wherein the ring(s) is/are 5- or 6-membered and wherein one or more of the rings contain at least one heteroatom,

30

or a radical chosen from the group consisting of

-77-



wherein X, Y, Z, independently from one another, each represent a radical selected from the group consisting of hydrogen, fluorine, chlorine, bromine, linear or branched C₁-C₆ alkyl, linear or branched C₁-C₆ alkoxy, linear or branched C₁-C₆ alkylthio, a trifluoromethyl radical, a cyano radical and a -NR¹²R¹³ radical,

wherein R¹² and R¹³, identical or different, each represent hydrogen or linear or branched C₁-C₆ alkyl,

W represents a single chemical bond between the two rings, a CH₂, O, S group or a NR¹⁴ radical,

wherein R¹⁴ is hydrogen or a linear or branched C₁-C₆ alkyl,

m is 0, 1, 2, 3 or 4 and

m₁ is 1 or 2.


14. A compound according to one or more of claims 9 to 13, selected from the group consisting of

- 5 [1] N-[1-(2-Dimethylaminoethyl)-1H-indol-6-yl]-5-chloro-3-methylbenzo[b]thiophene-2-sulfonamide,
- [2] N-[1-(2-Dimethylaminoethyl)-1H-indol-6-yl]-naphthalene-2-sulfonamide,
- 10 [3] N-[1-(2-Dimethylaminoethyl)-1H-indol-6-yl]-naphthalene-1-sulfonamide,
- [4] N-[1-(2-Dimethylaminoethyl)-1H-indol-6-yl]-6-chloroimidazo[2,1-b]thiazole-5-sulfonamide,
- 15 [5] N-[1-(2-Dimethylaminoethyl)-1H-indol-6-yl]-4-phenylbenzenesulfonamide,
- [6] N-[1-(2-Dimethylaminoethyl)-1H-indol-6-yl]-2-(naphthalene-1-yl)ethanesulfonamide,
- 20 [7] N-[1-(2-Dimethylaminoethyl)-1H-indol-6-yl]-4-phenoxybenzenesulfonamide,
- 25 [8] N-[1-(2-Dimethylaminoethyl)-1H-indol-6-yl]-3,5-dichlorobenzenesulfonamide,

and their corresponding salts and solvates.


-79-

15. A process for obtaining a sulfonamide derivative of general formula (Ia) and/or (Ib), according to one or more of claims 1 to 14, characterized in that at least one compound of general formula (II), or one of its suitably protected derivatives,



(II)

wherein A has the meaning according to one or more of claims 1 to 14 and X is an acceptable leaving group, preferably an halogen atom, more preferably chlorine; is reacted with at least one 6-aminoindole of general formula (III), or one of its suitably protected derivatives;



(III)

wherein R¹ to R⁷ and n have the meaning according to one or more of claims 1 to 14 to yield the corresponding sulfonamide and optionally, from the latter, the protective groups can be removed if necessary.

16. A process for obtaining a sulfonamide derivative of general formula (Ia) and/or (Ib), according to one or more of claims 1 to 14, wherein R¹ to R⁵, R⁷, n and A have the meaning according to one or more of claims 1 to 14, and R⁶ is C₁-C₆ alkyl, characterized in that at least one compound of general formula (Ia) and/or at least one compound of general formula (Ib), wherein R¹ to R⁵, R⁷, n and A have the meaning according to one or more of claims 1 to 14, and R⁶ is an hydrogen atom, is reacted with an alkyl halogenide or dialkyl sulfate.

17. A process for preparing the salts, preferably the physiologically acceptable salts of the compounds of general formula (Ia) and/or (Ib), according to one or more of claims 1 to 14, characterized in that at least one compound of the general formula (Ia) and/or at least one compound of the general formula (Ib) is reacted with a mineral acid or an organic acid in a suitable solvent.
18. A medicament comprising at least one compound according to one or more of claims 1 to 8 and optionally one or more pharmacologically acceptable excipients.
19. A medicament according to claim 18, for 5-HT₆ receptor regulation, for the prophylaxis and/or treatment of a disorder or disease related to food intake, preferably for the regulation of appetite, for the maintenance, increase or reduction of body weight, for the prophylaxis and/or treatment of obesity, bulimia, anorexia, cachexia or type II diabetes (non insulin dependent diabetes mellitus), preferably type II diabetes caused by obesity, for the prophylaxis and/or treatment of gastrointestinal tract disorders, preferably irritable bowel syndrome, for cognitive enhancement, for the prophylaxis and/or treatment of disorders of the central nervous system, anxiety, panic disorders, depression, bipolar disorders, cognitive memory disorders, senile dementia processes, neurodegenerative disorders, preferably Alzheimer's disease, Parkinson's disease, Huntington's disease and/or multiple sclerosis, schizophrenia, psychosis or infantile hyperkinesia (ADHD, attention deficit / hyperactivity disorder), preferably for 5-HT₆ receptor regulation, for the prophylaxis and/or treatment of a disorder or disease related to food intake, preferably for the regulation of appetite, for the maintenance, increase or reduction of body weight, for the prophylaxis and/or treatment of obesity, bulimia,

anorexia, cachexia or type II diabetes (non insulin dependent diabetes mellitus), preferably type II diabetes caused by obesity, for the prophylaxis and/or treatment of gastrointestinal tract disorders, preferably irritable bowel syndrome.

5

20. The use of at least one compound according to one or more of claims 1 to 8 for the manufacture of a medicament for 5-HT₆ receptor regulation.

10

21. The use of at least one compound according to one or more of claims 1 to 8 for the manufacture of a medicament for the prophylaxis and/or treatment of a disorder or disease related to food intake.

15

22. The use of at least one compound according to one or more of claims 1 to 8 for the manufacture of a medicament for the regulation of appetite.

23. The use of at least one compound according to one or more of claims 1 to 8 for the manufacture of a medicament for the maintenance, increase or reduction of body weight.

20

24. The use of at least one compound according to one or more of claims 1 to 8 for the manufacture of a medicament for the prophylaxis and/or treatment of obesity.

25

25. The use of at least one compound according to one or more of claims 1 to 8 for the manufacture of a medicament for the prophylaxis and/or treatment of bulimia.

30

26. The use of at least one compound according to one or more of claims 1 to 8 for the manufacture of a medicament the prophylaxis and/or treatment of anorexia.

27. The use of at least one compound according to one or more of claims 1 to 8 for the manufacture of a medicament for the prophylaxis and/or treatment of cachexia.
- 5 28. The use of at least one compound according to one or more of claims 1 to 8 for the manufacture of a medicament for the prophylaxis and/or treatment of type II diabetes (non insulin dependent diabetes mellitus), preferably type II diabetes caused by obesity.
- 10 29. The use of at least one compound according to one or more of claims 1 to 8 for the manufacture of a medicament for the prophylaxis and/or treatment of gastrointestinal tract disorders.
- 15 30. The use of at least one compound according to one or more of claims 1 to 8 for the manufacture of a medicament for the prophylaxis and/or treatment of irritable bowel syndrome.
- 20 31. The use of at least one compound according to one or more of claims 1 to 8 for the manufacture of a medicament for the prophylaxis and/or treatment of anxiety.
- 25 32. The use of at least one compound according to one or more of claims 1 to 8 for the manufacture of a medicament for the prophylaxis and/or treatment of depression.
- 30 33. The use of at least one compound according to one more of claims 1 to 8 for the manufacture of a medicament for the prophylaxis and/or treatment of bipolar disorders.
34. The use of at least one compound according to one or more of claims 1 to 8 for the manufacture of a medicament for the prophylaxis and/or treatment of cognitive memory disorders.

35. The use of at least one compound according to one or more of claims 1 to 8 for the manufacture of a medicament for the prophylaxis and/or treatment of senile dementia processes.
- 5
36. The use of at least one compound according to one or more of claims 1 to 8 for the manufacture of a medicament for the prophylaxis and/or treatment of Alzheimer's Disease.
- 10
37. The use of at least one compound according to one or more of claims 1 to 8 for the manufacture of a medicament for the prophylaxis and/or treatment of Parkinson's Disease.
- 15
38. The use of at least one compound according to one or more of claims 1 to 8 for the manufacture of a medicament for the prophylaxis and/or treatment of Huntington's Disease.
- 20
39. The use of at least one compound according to one or more of claims 1 to 8 for the manufacture of a medicament for the prophylaxis and/or treatment of dementias in which a cognitive deficit predominates.
- 25
40. The use of at least one compound according to one or more of claims 1 to 8 for the manufacture of a medicament for the prophylaxis and/or treatment of Multiple Sclerosis.
- 30
41. The use of at least one compound according to one or more of claims 1 to 8 for the manufacture of a medicament for the prophylaxis and/or treatment of psychosis.

42. The use of at least one compound according to one or more of claims 1 to 8 for the manufacture of a medicament for the prophylaxis and/or treatment of infantile hyperkinesia (ADHD, attention deficit / hyperactivity disorder).
- 5
43. The use of at least one compound according to one or more of claims 1 to 8 for the manufacture of a medicament for the prophylaxis and/or treatment of disorders of the central nervous system.
- 10
44. The use of at least one compound according to one or more of claims 1 to 8 for the manufacture of a medicament for the prophylaxis and/or treatment of schizophrenia.
- 15
45. The use of at least one compound according to one or more of claims 1 to 8 for the manufacture of a medicament for cognitive enhancement.
- 20
46. A medicament comprising at least one compound according to one or more of claims 9 to 14 and optionally one or more pharmacologically acceptable excipients.
- 25
47. A medicament according to claim 46 for 5-HT₆ receptor regulation, for the prophylaxis and/or treatment of a disorder or disease related to food intake, preferably for the regulation of appetite, for the maintenance, increase or reduction of body weight, for the prophylaxis and/or treatment of obesity, bulimia, anorexia, cachexia or type II diabetes (non insulin dependent diabetes mellitus), preferably type II diabetes caused by obesity, for the prophylaxis and/or treatment of gastrointestinal tract disorders, preferably irritable bowel syndrome, for cognitive enhancement, for the prophylaxis and/or treatment of disorders of the central nervous system, anxiety, panic disorders, depression, bipolar disorders, cognitive memory disorders, senile dementia processes, neurodegenerative disorders, preferably Alzheimer's disease,
- 30

Parkinson's disease, Huntington's disease and/or multiple sclerosis, schizophrenia, psychosis or infantile hyperkinesia (ADHD, attention deficit / hyperactivity disorder),

- 5 preferably for cognitive enhancement, for the prophylaxis and/or treatment of disorders of the central nervous system, anxiety, panic disorders, depression, bipolar disorders, cognitive memory disorders, senile dementia processes, neurodegenerative disorders, preferably
- 10 Alzheimer's disease, Parkinson's disease, Huntington's disease and /or multiple sclerosis, schizophrenia, psychosis or infantile hyperkinesia (ADHD, attention deficit / hyperactivity disorder).
48. The use of at least one compound according to one or more of claims 9 to 14 for the manufacture of a medicament for 5-HT₆ receptor regulation.
- 15 49. The use of at least one compound according to one or more of claims 9 to 14 for the manufacture of a medicament for the prophylaxis and/or treatment of a disorder or disease related to food intake.
- 20 50. The use of at least one compound according to one or more of claims 9 to 14 for the manufacture of a medicament for the regulation of appetite.
51. The use of at least one compound according to one or more of claims 9 to 14 for the manufacture of a medicament for the maintenance, increase
- 25 or reduction of body weight.
52. The use of at least one compound according to one or more of claims 9 to 14 for the manufacture of a medicament for the prophylaxis and/or treatment of obesity.

53. The use of at least one compound according to one or more of claims 9 to 14 for the manufacture of a medicament for the prophylaxis and/or treatment of bulimia.
- 5 54. The use of at least one compound according to one or more of claims 9 to 14 for the manufacture of a medicament for the prophylaxis and/or treatment of anorexia.
- 10 55. The use of at least one compound according to one or more of claims 9 to 14 for the manufacture of a medicament for the prophylaxis and/or treatment of cachexia.
- 15 56. The use of at least one compound according to one or more of claims 9 to 14 for the manufacture of a medicament for the prophylaxis and/or treatment of type II diabetes (non-insulin-dependent diabetes mellitus), preferably type II diabetes caused by obesity.
- 20 57. The use of at least one compound according to one or more of claims 9 to 14 for the manufacture of a medicament for the prophylaxis and/or treatment of gastrointestinal tract disorders.
- 25 58. The use of at least one compound according to one or more of claims 9 to 14 for the manufacture of a medicament for the prophylaxis and/or treatment of irritable bowel syndrome.
- 30 59. The use of at least one compound according to one or more of claims 9 to 14 for the manufacture of a medicament for the prophylaxis and/or treatment of anxiety.

60. The use of at least one compound according to one or more of claims 9 to 14 for the manufacture of a medicament for the prophylaxis and/or treatment of depression.
- 5 61. The use of at least one compound according to one or more of claims 9 to 14 for the manufacture of a medicament for the prophylaxis and/or treatment of bipolar disorders.
- 10 62. The use of at least one compound according to one or more of claims 9 to 14 for the manufacture of a medicament for the prophylaxis and/or treatment of cognitive memory disorders.
- 15 63. The use of at least one compound according to one or more of claims 9 to 14 for the manufacture of a medicament for the prophylaxis and/or treatment of senile dementia processes.
- 20 64. The use of at least one compound according to one or more of claims 9 to 14 for the manufacture of a medicament for the prophylaxis and/or treatment of Alzheimer's Disease.
- 25 65. The use of at least one compound according to one or more of claims 9 to 14 for the manufacture of a medicament for the prophylaxis and/or treatment of Parkinson's Disease.
- 30 66. The use of at least one compound according to one or more of claims 9 to 14 for the manufacture of a medicament for the prophylaxis and/or treatment of Huntington's Disease.
67. The use of at least one compound according to one or more of claims 9 to 14 for the manufacture of a medicament for the prophylaxis and/or treatment of Multiple Sclerosis.

68. The use of at least one compound according to one or more of claims 9 to 14 for the manufacture of a medicament for the prophylaxis and/or treatment of dementias in which a cognitive deficit predominates.
- 5 69. The use of at least one compound according to one or more of claims 9 to 14 for the manufacture of a medicament for the prophylaxis and/or treatment of psychosis.
- 10 70. The use of at least one compound according to one or more of claims 9 to 14 for the manufacture of a medicament for the prophylaxis and/or treatment of infantile hyperkinesia (ADHD, attention deficit / hyperactivity disorder).
- 15 71. The use of at least one compound according to one or more of claims 9 to 14 for the manufacture of a medicament for the prophylaxis and/or treatment of disorders of the central nervous system.
- 20 72. The use of at least one compound according to one or more of claims 9 to 14 for the manufacture of a medicament for the prophylaxis and/or treatment of schizophrenia.
- 25 73. The use of at least one compound according to one or more of claims 9 to 14 for the manufacture of a medicament for cognitive enhancement.